Journal Papers, Abstracts, and Commentaries

• Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.
  Brites C, Nóbrega I, Luz E, et al 
  HIV Clin Trials. 2018 Apr 9:1
  Abstract

• Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
  Kreutzwiser D, Sheehan N, Dayneka N, et al  
  Antivir Ther. 2017 Feb 15.
  Abstract

• FULL-TEXT PDF ARTICLE
  An HIV-infected Pregnant Woman Treated with the Long-term Administration of Antiretroviral Therapy Including Raltegravir.
  Yaita K, Inoue S, Horinouchi T, Kinoshita M, et al
  Intern Med. 2016;55(18):2727-30.
  Paper

• FULL-TEXT ARTICLE
  A case series of third-trimester raltegravir initiation: Impact on maternal HIV-1 viral load and obstetrical outcomes
  Boucoiran I, Tulloch K, Pick N,
  Can J Infect Dis Med Microbiol. 2015 May-Jun;26(3):145-50.
  Paper

• Raltegravir in HIV-1 Infected Pregnant Women: Pharmacokinetics, Safety and Efficacy.
  Blonk M, Colbers A, Hidalgo-Tenorio C,  et al
  Clin Infect Dis. 2015 May 5.
  Abstract

• Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates.
  Ripamonti D, Tatarelli P, Mangili G,  et al
  J Chemother. 2014 Sep 24:1973947814Y0000000217
  Abstract

• Pregnancy influences the plasma pharmacokinetics but not the cerebrospinal fluid pharmacokinetics of raltegravir: A preclinical investigation.
  Mahat MY, Thippeswamy BS, Khan FR,  et al
  Eur J Pharm Sci. 2014 Sep 6.
  Abstract

• Raltegravir Pharmacokinetics during Pregnancy.
  Watts DH, Stek A, Best BM, et al
  J Acquir Immune Defic Syndr. 2014 Aug 26.
  Abstract

• Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing.
  Clarke DF, Acosta EP, Rizk ML et al
  J Acquir Immune Defic Syndr. 2014 Aug 26.
  Abstract

• Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review.
  De Hoffer L, Di Biagio A, Bruzzone B, et al 
  J Chemother. 2013;25(3):181-3.
  Abstract

• Use  of  Raltegravir in Late Presenting  HIV-Infested  Pregnant  Women
  Nobrega I, Travassos AG, Haguihara T, et al
  AIDS Res Hum Retroviruses. 2013 Jun 3.
  Abstract

• HIV seroconversion in the third trimester of pregnancy: using raltegravir to prevent mother-to-child transmission.
  Hegazi A, Hay P.
  Int J STD AIDS. 2013 Feb 25.
  Abstract

• Increase in Transaminase Levels Following the Use of Raltegravir in a Woman With a High HIV Viral Load at 35 Weeks of Pregnancy.
  Renet S, Closon A, Brochet MS, et al
  J Obstet Gynaecol Can. 2013 Jan;35(1):68-72.
  Abstract

• Efficacy of raltegravir in late-presenting HIV-infected pregnant women: a case series presentation.
  Nobrega I, Travassos A, Haguihara T, Brites C.
  J Int AIDS Soc. 2012 Nov 11;15(6):18237
  Abstract

• Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates.
  Hegazi A, Mc Keown D, Doerholt K, et al
  AIDS. 2012 Nov 28;26(18):2421-3.
  Abstract

• Rapid Decline in HIV Viral Load When Introducing Raltegravir-Containing Antiretroviral Treatment Late in Pregnancy.
  Westling K, Pettersson K, Kaldma A, Navér L.
  AIDS Patient Care STDS. 2012 Oct 26.
  Abstract

• Pharmacokinetic and safety of raltegravir in pregnancy.
  Croci L, Trezzi M, Allegri MP,  et al
  Eur J Clin Pharmacol. 2012 Mar 1.
  Abstract

• Raltegravir in pregnancy: a case series presentation.
  Taylor N, Touzeau V, Geit M,  et al
  Int J STD AIDS. 2011 Jun;22(6):358-60.
  Abstract